GI Dynamics Announces Scientific Advisory Board Members to Further Development of EndoBarrier
May 08 2017 - 8:30AM
Business Wire
GI Dynamics®, Inc. (ASX:GID), a medical device company that has
commercialized EndoBarrier® in Europe, the Middle East and South
America for patients with type 2 diabetes and obesity, has
announced additional members of the GI Dynamics Scientific Advisory
Board (SAB), bringing together distinguished physicians and
scientists specializing in endocrinology, gastroenterology and
bariatric/metabolic surgery. Ricardo Cohen, MD, and Christopher
Thompson, MD, MHES, have joined the GI Dynamics SAB.
The GI Dynamics SAB was created to further advance the body of
evidence regarding EndoBarrier and advance the state of patient
care with EndoBarrier. The SAB will serve as a key resource for GI
Dynamics during the Investigational Device Exemption clinical trial
of EndoBarrier in the United States as well as supporting ongoing
clinical studies and the commercialization process in the United
Kingdom, Germany, the Middle East, and select European
countries.
“Dr. Cohen and Dr. Thompson will be valued members of the GI
Dynamics SAB,” said Scott Schorer, GI Dynamics president and CEO.
“Dr. Cohen is a leader in the type 2 diabetes and obesity field and
has developed a rich history with EndoBarrier, starting with early
clinical work. Dr. Thompson is a gifted gastroenterologist with
deep experience in complex primary and revision procedures. He is
highly experienced in new technology development and generates
significant research through his clinical team,” concluded
Schorer.
Dr. Cohen is the director for the Center for Obesity and
Diabetes at the Oswaldo Cruz German Hospital located in São Paulo,
Brazil. Dr. Cohen is also the former president of the Brazilian
Society of Bariatric and Metabolic Surgery, and is the current
president of the International Federation for the Surgery of
Obesity and Metabolic Disorders (IFSO), Latin America Chapter.
Dr. Cohen has been the primary investigator (PI) for 15 studies,
including two EndoBarrier studies. He has published more than 150
papers and is considered a leader in the field of surgery for
patients with type 2 diabetes and non-severe obesity.
“GI Dynamics with EndoBarrier has produced an excellent adjuvant
tool to achieve diabetes control,” said Dr. Cohen. “I look forward
to helping GI Dynamics continue to develop EndoBarrier to provide a
safe and effective device in a treatment area that is growing
rapidly.”
Dr. Thompson is the director of Therapeutic Endoscopy at Brigham
Women's Hospital and an associate professor of Medicine at Harvard
Medical School in Massachusetts. He is also the current chair of
the Association of Bariatric Endoscopy (ABE). He started his career
in medicine after receiving his MD from Pennsylvania State
University, College of Medicine in Hershey, Pennsylvania. He went
on to receive his MSc in health evaluation science.
Dr. Thompson has more than 200 academic publications to his
name, and he has been the PI in numerous clinical trials. He is
particularly well-known for his work on metabolic therapies for
obesity. He is the editor of the first textbook on bariatric
endoscopy, and he has trained numerous fellows in the field.
“EndoBarrier is an exciting and novel technology that fills a
rapidly expanding treatment gap in the management of type 2
diabetes and obesity. The GI Dynamics team has pioneered the
advancement of our understanding of disease and treatment
mechanisms over the past decade, and this device holds tremendous
promise,” said Dr. Thompson. “I am thrilled to be joining such an
accomplished group of clinicians and look forward to collaborating
with them.”
About GI Dynamics
GI Dynamics, Inc. (ASX:GID), is the developer of EndoBarrier,
the first endoscopically-delivered device therapy approved for the
treatment of type 2 diabetes and obesity. EndoBarrier is approved
and commercially available in multiple countries outside the United
States. EndoBarrier is not approved for sale in the United
States and is limited by federal law to investigational use only in
the United States. Founded in 2003, GI Dynamics is headquartered in
Boston, Massachusetts. For more information, please
visit www.gidynamics.com.
Forward-Looking Statements
This announcement contains forward-looking statements concerning
our development and commercialization plans, potential revenues and
revenue growth, costs, excess inventory, profitability and
financial performance, ability to obtain reimbursement for our
products, clinical trials and associated regulatory submissions and
approvals, the number and location of commercial centers offering
the EndoBarrier, and our intellectual property position. These
forward-looking statements are based on GI Dynamics’ management’s
current estimates and expectations of future events as of the date
of this announcement. Furthermore, the estimates are subject to
several risks and uncertainties that could cause actual results to
differ materially and adversely from those indicated in or implied
by such forward-looking statements. These risks and uncertainties
include but are not limited to, risks associated with the
consequences of terminating the ENDO trial and the possibility that
future clinical trials will not be successful or confirm earlier
results. Further risks are associated with obtaining funding from
third parties; the timing and costs of clinical trials; the timing
of regulatory submissions; and the timing, receipt and maintenance
of regulatory approvals. The timing and amount of other expenses
and the timing and extent of third-party reimbursement risks
associated with commercial product sales, including product
performance, competition, risks related to market acceptance of
products, intellectual-property risk; risks related to excess
inventory; and risks related to assumptions regarding the size
of the available market, the benefits of our products, product
pricing, timing of product launches, future financial results and
other factors, including those described in our filings with the
U.S. Securities and Exchange Commission. Given these uncertainties,
one should not place undue reliance on these forward-looking
statements. We do not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information or future events or otherwise, unless we are required
to do so by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170508005746/en/
Investor RelationsUnited States:GI DynamicsJanell
Shields, +1-781-357-3280orMedia RelationsUnited States:JPA
Health CommunicationsNicole Franklin, +1-617-657-1312
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Apr 2023 to Apr 2024